Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAbdullah KhanAOAlbert OriolMGMercedes Gironella

Discussion

Loading...

Member takes

Overview

Subgroup analysis shows no impact of renal function on efficacy and safety outcomes in multiple myeloma patients treated with IberDd.

Key Points

  • Overall response rate was 94.6%, with similar rates across renal function subgroups, indicating robust efficacy.
  • Neutropenia was observed in 78.4% of patients overall, with varying incidences based on renal function categories.
  • Published evidence suggests no correlation between renal function and key efficacy or safety endpoints during treatment.
  • These findings support the safety of Iberdomide dosing without modifications for renal impairment in multiple myeloma patients.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de2ehttps://doi.org/10.1182/blood-2025-5810
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial2025 · 1 citations
  2. 2Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial2025 · 5 citations
  3. 3Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study2025
  4. 4An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01.2025 · 1 citations
  5. 5Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 8 citations